Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The incidence of pediatric-onset inflammatory bowel disease (IBD) and the costs of caring for individuals with IBD are both increasing. We calculated the direct healthcare costs of pediatric IBD in the first year after diagnosis and developed a model to predict children who would have high costs (top 25th percentile).

Methods: Using data from the Canadian Children IBD Network inception cohort (≤16 years of age, diagnosed between 2013 and 2019) deterministically linked to health administrative data from Ontario, Canada, we estimated direct healthcare and medication costs accrued between 31 and 365 days after diagnosis. Candidate predictors included age at diagnosis, sex, rural/urban residence location, distance to pediatric center, neighborhood income quintile, IBD type, initial therapy, disease activity, diagnostic delay, health services utilization or surgery around diagnosis, regular primary care provider, and receipt of mental health care. Logistic regression with stepwise elimination was used for model building; 5-fold nested cross-validation optimized and improved model accuracy while limiting overfitting.

Results: The mean cost among 487 children with IBD was CA$15 168 ± 15 305. Initial treatment (anti-tumor necrosis factor therapy, aminosalicylates, or systemic steroids), having a mental health care encounter, undergoing surgery, emergency department visit at diagnosis, sex, and age were predictors of increased costs, while having a regular primary care provider was a predictor of decreased costs. The C-statistic for our model was 0.71.

Conclusions: The cost of caring for children with IBD in the first year after diagnosis is immense and can be predicted based on characteristics at diagnosis. Efforts that mitigate rising costs without compromising quality of care are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izae148DOI Listing

Publication Analysis

Top Keywords

children ibd
12
costs
8
healthcare costs
8
inflammatory bowel
8
bowel disease
8
health administrative
8
administrative data
8
direct healthcare
8
ibd year
8
year diagnosis
8

Similar Publications

Host - microbiome interactions are central to Crohn'sdisease (CD) pathogenesis; yet the early metabolic alterations that precededisease onset remain poorly defined. To explore preclinical metabolicsignatures of CD, we analyzed baseline serum metabolomic profiles in a nestedcase-control study within the Crohn's and Colitis Canada - Genetics, Environment, Microbiome (CCC-GEM) Project, a prospective cohort of 5,122 healthyfirst-degree relatives (FDRs) of CD patients. We included 78 individuals wholater developed CD and 311 matched FDRs who remained disease-free.

View Article and Find Full Text PDF

Background/aims: Early-onset inflammatory bowel disease (EO-IBD) poses a global health challenge with its distinct clinical manifestations and complex progression.

Methods: In this study, IBD cases occurring before age 20 were defined as EO-IBD. Data were extracted from the Global Burden of Disease 2021 database.

View Article and Find Full Text PDF

Median arcuate ligament syndrome: challenges, comorbidities, and controversies.

Curr Opin Pediatr

October 2025

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Stanford University School of Medicine and Stanford Children's Health, Palo Alto, California, USA.

Purpose Of Review: Median arcuate ligament syndrome (MALS) is understood to be a condition where compression of the celiac artery by the median arcuate ligament (MAL) may lead to symptoms of postprandial or exercise-induced abdominal pain, nausea, vomiting, diarrhea, oral aversion, and weight loss. This review summarizes recent literature on pediatric MALS while highlighting the challenges, comorbidities, and controversies encountered in this condition.

Recent Findings: The pathophysiologic mechanism by which MALS leads to pain is currently unknown.

View Article and Find Full Text PDF

A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy.

Clin Res Hepatol Gastroenterol

September 2025

Pediatric Hepato-Gastroenterology and Nutrition Unit, Hôpital Femme Mère Enfant de Lyon Hôpital Femme Mère Enfant, Hospices Civils de Lyon HCL, Bron, France; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm),

Objective: Infliximab is approved for pediatric Crohn's disease (CD) and ulcerative colitis (UC), but is limited in children by its intravenous administration. We evaluated the effectiveness and safety of switching from intravenous to subcutaneous infliximab in pediatric patients with CD/UC.

Methods: Multicenter retrospective cohort study, from January to December 2022 in two pediatric centers, that included CD/UC patients in clinical remission and weighing ≥50 kg, treated with maintenance dose IV IFX.

View Article and Find Full Text PDF

Restroom access acts (RAAs) provide persons with inflammatory bowel disorders (IBD) and other health conditions emergency access to a business's employee restroom. Despite the important role these laws can play in supporting a person's health and dignity, they remain understudied. This Article is the first to explore what if any role a RAA has in the lives of persons living with IBD.

View Article and Find Full Text PDF